The research, published in BMC Geriatrics , examined clinicians’ views on what, how and why neuropsychological assessment results are communicated. The investigators conducted two focus groups with physicians and two focus groups with psychologists. Participants were experienced clinicians working in Dutch memory clinics, and two independent researchers analysed the accounts using deductive thematic content analysis.

This design explored professional perspectives through qualitative discussion; it did not measure patient outcomes or establish whether any particular communication strategy improves understanding, disease acceptance or clinical care. Participants described neuropsychological assessments as central to memory-clinic diagnostics and closely integrated with other diagnostic tests. Because these assessments provide detailed information about cognitive functioning and daily life, clinicians said they use the results as part of a broader diagnostic explanation rather than communicating them in isolation.

Their accounts emphasized personalized, structured disclosure, with strategies aimed at helping recipients understand the findings and manage emotional responses. The findings show that clinicians view neuropsychological assessment not only as a diagnostic instrument but also as a resource for matching communication to the people receiving the results. Clinicians also placed the disclosure within a wider process.

Although they saw disease acceptance as extending beyond the memory clinic, they recognized that communication during the diagnostic or neuropsychological disclosure may influence how patients first understand and adjust to information about a possible neurodegenerative disease. The authors conclude that optimizing how results are conveyed may improve patient understanding and the quality of memory-clinic care.

Subject of Research: How Dutch memory-clinic professionals communicate neuropsychological assessment results to patients and informal caregivers

Article Title: Communicating neuropsychological assessment results: a qualitative study in Dutch memory clinic professionals

Article References: Stolte, M., Dobbe, J. H. M., Visser, L. N. C., Smets, E., Jansen, W. J., de Vugt, M., & Ramakers, I. (2026). Communicating neuropsychological assessment results: a qualitative study in Dutch memory clinic professionals. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08529-w

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08529-w

Keywords: neuropsychological assessment, memory clinics, diagnostic communication, patient understanding, caregiver communication, disease acceptance, qualitative research, focus groups, cognitive functioning, Dutch clinicians, Communicating, neuropsychological

The scale of the underlying problem gives this work urgency. As global populations age, the number of people living with dementia continues to climb, and the complexities of the condition demand care systems that can genuinely meet the needs of both those diagnosed and their care partners. Policy provides the foundation for that care, yet national approaches vary enormously, shaped by regulatory environments and unique sociocultural contexts. The editors argue that this variation is not merely a complication but an opportunity: it creates a natural laboratory of innovative programs, networks and policies that make non-clinical services accessible, and sharing these innovations widely is essential to improving access everywhere. Five thematic areas emerged from the submissions: access for underserved populations, nature-based supports, creative pursuits, specific policies, and technological innovations for care and support.

Equity stands out as the collection’s most sobering thread. Barriers to dementia prevention, diagnosis, care and support are amplified for populations facing social disadvantage, cultural exclusion, geographic isolation, low income or migration, and these inequities are associated with worse brain health. The articles respond with models built from the ground up. Bell and colleagues describe a Multimodal Intergenerational Social Contact Intervention, a community-embedded program targeting dementia risk factors of loneliness and depressed mood through culturally meaningful intergenerational engagement. Nair and colleagues propose a Community Health and Wellbeing Worker-led model that strengthens existing neighborhood-based roles to deliver proactive, culturally responsive dementia support across the care continuum, offering a scalable route to earlier identification and better continuity for underserved communities.

The inequities documented are stark and global. In an original research article from Peru, Custodio and Dorell explore how family care partners experience and manage the behavioral and psychological symptoms of dementia, revealing the emotional toll of caregiving and the need for culturally responsive supports in Latin America. In Canada, Fischer and colleagues found that a web-based educational program on dementia risk factors was culturally inappropriate for Métis communities in Alberta, concluding that in-person engagement is crucial to co-develop resources reflecting Indigenous knowledge and worldviews. A review led by Aguzzoli and colleagues, focused largely on Europe and the United States, highlights persistent inequalities among ethnic minority groups, including reduced access to primary care and lower treatment adherence compared with majority counterparts. Meanwhile, Solis and colleagues describe a decade of experience at a public memory clinic in Argentina serving a predominantly low-income region, showing how specialized dementia care can be adapted to an underserved population, and DeDecker and colleagues report an Ontario program embedding structured cognitive and functional assessments within community organizations, sharing results with primary care providers and linking standardized data to a provincial registry that informs policy in real time.

One of the most unexpectedly vibrant themes is the role of nature. Nature-based programs for people living with dementia and their care partners have been shown to improve mental health, physical activity, cognitive stimulation and social connection, yet cost, limited awareness, mobility challenges, environmental design and dementia-related stigma keep many from accessing them. Thompson and colleagues present a mini review of nature-based living labs, extending their application from indoor settings and aged care systems to direct engagement with the natural world. In Northern Italy, Dalla Costa and colleagues describe how farms can become places where people with dementia are empowered as active participants in meaningful shared work rather than passive recipients of care, a low-cost intervention that capitalizes on existing agricultural resources and volunteer frameworks and can be adapted to other community contexts. A review by Gill and colleagues in the United Kingdom maps evidence that both indoor and outdoor nature-based interventions can benefit psychological health, wellbeing and social engagement for people with dementia and those who care for them.

Creative pursuits emerge as another powerful, evidence-backed frontier, aligned with the World Health Organization’s growing arts and health movement. The logic is neurologically compelling: dementia shifts abilities unevenly, so while some cognitive domains decline, others remain intact, and creative practices in music, visual arts, storytelling and performance can support identity, evoke emotional expression and strengthen relationships in ways biomedical approaches alone cannot. Delacourt and colleagues describe a Canadian assisted living setting where co-viewing emotionally positive videos with people with advanced dementia elicits rich emotional communication through vocalizations, gaze and facial expressions, fostering social connection and joy. Huang and colleagues systematically review the use of headphones in music programs within long-term care, identifying enablers and barriers to personalized music therapy. An international group including people with lived experience, led by Liougas and colleagues, describes Walking the Talk for Dementia, a global immersive multi-day event that shifts the narrative from deficit-focused models toward creativity, resilience and shared humanity. In a striking fusion of art and neuroscience, O’Kelly and colleagues describe an initiative that transforms segments of a person’s EEG brain activity into colored spectrograms rendered as stained glass installed in their own home.

Policy itself receives direct scrutiny, with the editors noting that existing programs are often inadequate in scope and scale to create equitable care systems. Roberts and colleagues report on the adaptation of the Alzheimer’s and Dementia Care ECHO Program, finding that increased recognition of dementia risk reduction strategies among public health professionals can lead to more proactive measures integrated into local and regional strategies. Nakakawa and colleagues illuminate how dementia policy translates into everyday homecare practice in Sweden, showing that person-centered care requires more than formal policy commitments; their participatory, design-driven methods create spaces for collective sensemaking across system levels, bridging the gap between policy ideals and municipal realities. In the United States, Carder and colleagues found that states with memory-care-specific assisted living regulations were far more likely to include detailed person-centered and family-involved care requirements, covering staff training, care planning, resident rights and social engagement. Snowball and colleagues, in Canada, argue that lived experience should be recognized as a form of expertise in shaping research, policy and advocacy, supported through sustained participation and accessible infrastructures.

Technology rounds out the collection with both promise and caution. Tsabary and colleagues report an INTERDEM study mapping 28 research initiatives involving digital technology use by people with dementia during the COVID-19 pandemic, yielding a consensus-based framework to guide the adoption and implementation of assistive technologies. A review by Szcześniak and colleagues shifts attention from technology availability to equitable implementation, calling for personalizable, usable, diversity-sensitive technologies that support social health, independence and meaningful engagement. Kafadar and colleagues examine online peer support for people affected by young-onset dementia, emphasizing equitable, age-appropriate, co-designed approaches for populations facing geographic, digital and stigma-related barriers. From Spain and the Netherlands, Vilor-Tejedor and colleagues acknowledge artificial intelligence’s potential to enhance care delivery and decision-making but insist its development and governance must be grounded in dignity, equity, privacy and human connection, ensuring that technology augments rather than replaces human care. Timmons and colleagues demonstrate that peer support embedded within an online education program reduced isolation and increased confidence among caregivers.

The overarching message from the editors is one of momentum and transferability. Innovation, they conclude, is essential to meet the growing global need associated with dementia, and individuals and organizations worldwide are already developing approaches that transcend traditional services, including national and regional policies that can travel across jurisdictions. From Ontario’s standardized assessment registries to Italian care farms, from EEG-derived stained glass to Sweden’s design-driven sensemaking workshops, the diversity of innovations documented here suggests the future of dementia care will be built as much in communities and parliaments as in clinics. For researchers, practitioners and policymakers alike, the collection invites a simple but demanding question: which of these ideas can be adapted, tested and scaled in their own systems, before the demographic wave makes the answers a matter of urgency rather than aspiration.

Subject of Research: Global innovations in dementia care policies, services, equity, nature-based programs, creative arts and assistive technology

Article Title: Editorial: Innovations in dementia policies and services

Article References: Dawson, W. D., Canty, A. J., Migeot, J., O'Philbin, L., & Gelmon, S. B. (2026). Editorial: Innovations in dementia policies and services. Frontiers in Dementia, 5, Article 2006454. https://doi.org/10.3389/frdem.2026.2006454

Image Credits: AI Generated

DOI: 10.3389/frdem.2026.2006454

Keywords: dementia, health policy, caregiving, health equity, nature-based interventions, creative arts therapy, assistive technology, artificial intelligence, memory clinics, Indigenous health, person-centered care, global brain health

The research team, led by Sarah Jane Smith of the Centre for Dementia Research at Leeds Beckett University, recorded consultations involving ten clinicians, twenty-nine patients and thirty-two relatives or supporters. This is a technically demanding kind of study to pull off. Recording real clinical encounters requires ethical approval, patient consent and careful handling of sensitive moments in people’s lives, and the study was approved by the National Research Ethics Service committee for Yorkshire and The Humber in March 2021, with adaptations for verbal and audio-recorded consent during the COVID-19 pandemic. Once recorded, the consultations were subjected to content analysis, a systematic method in which researchers code the talk against predefined categories to identify patterns in what is communicated, how often, and in what form. The approach allows researchers to move beyond anecdote and quantify precisely how treatment information is being delivered in routine practice.

The most consistent finding concerned how benefits were presented. In twenty-six of the twenty-nine consultations, clinicians framed the purpose of dementia medication as symptom management, and within that framing the dominant emphasis was on memory and cognition. That makes clinical sense, because the pharmacological treatments available for dementia, such as the cholinesterase inhibitors commonly prescribed for Alzheimer’s disease, are licensed to treat symptoms rather than to halt the underlying neurodegenerative disease. Yet the consistency ended there. In only thirteen of the twenty-nine consultations did clinicians explicitly state that the treatment was not curative, meaning that in more than half of the encounters patients may have left the room without a clear verbal statement that the drug could not stop or reverse their condition.

More surprising still was the language used to describe what the drugs might achieve beyond symptoms. In roughly one third of consultations, clinicians at some point suggested that treatment might be disease modifying, a claim that overstates the established evidence base for currently licensed dementia medications. Around half of the consultations referred to symptom reduction or delay. The researchers characterise this overall pattern as positive framing of treatment benefits, and the technical concern underlying it is well recognised in health communication research: when clinicians use leading or optimistic language about a therapy’s effects, patients can develop expectations that outstrip what the evidence supports, which in turn complicates decisions about continuing or stopping medication when benefits fail to materialise.

Side effects, by contrast, were discussed almost universally, appearing in twenty-six of the twenty-nine consultations. But the manner of that discussion revealed its own patterns. Clinicians frequently deployed verbal qualifiers, small linguistic hedges that signal the certainty or likelihood of an effect, such as indicating that something happens only occasionally or might occur. Qualifiers are not inherently problematic; they are a natural way of conveying probability in everyday speech. The difficulty arises when they are applied inconsistently, because a patient hearing that a side effect is possible in one consultation and unlikely in another receives materially different information about the same drug.

Perhaps the most consequential finding was how side effects were characterised when they were raised. The study found that the side effect profile was commonly described in minimising terms, presented as not serious or downplayed relative to the potential benefits. For patients and families weighing whether to start a medication, this framing matters enormously. Nausea, loss of appetite, vivid dreams and other recognised effects of dementia drugs can be distressing enough to prompt discontinuation, and a patient who has been told the effects are minor may feel misled when they experience them. The authors also note that explicit discussions weighing risks against benefits, the kind of balanced deliberation that shared decision-making ideally requires, occurred in only half of the consultations.

There was at least one area where communication fell short in a more mechanical way. In thirteen consultations, clinicians explained how the treatments actually work, the mechanism of action, and in eight of those the explanation was delivered in a patient-friendly way. That means fewer than a third of all consultations included an accessible account of the drug’s mechanism. For a population in which cognitive impairment is the defining feature, understanding how a medication is supposed to act is not a luxury; it is foundational to adherence, to monitoring for effects, and to making sense of follow-up appointments where treatment continuation is decided.

The variability the researchers documented is not simply a matter of individual clinician style. Because the consultations took place across two NHS Trusts with ten different clinicians, the inconsistency suggests an absence of shared standards for how dementia treatment information should be conveyed. The authors respond with three concrete recommendations. First, clinicians should exercise caution about using leading language that frames benefits optimistically without evidential warrant, including suggestions that drugs may modify the disease. Second, communication about both benefits and side effects should be consistent and transparent, so that patients receive comparable information regardless of which clinician they see. Third, evidence-based patient decision aids should be employed where appropriate, giving patients structured, balanced written or visual support to complement the spoken consultation.

The stakes of getting this right are considerable. Decisions about whether to take dementia medication are made at a moment when patients and families are absorbing a life-changing diagnosis, and the study’s authors point out that these discussions have a direct impact on the decision to take treatments, on understanding of the medications, and on adherence over time. A patient who believes a drug will slow their disease may persist with it despite troublesome side effects and no perceived benefit; a patient who was never told the treatment is not curative may face that realisation later without clinical support. Communication in the consultation is, in effect, the first dose of the treatment.

The research, funded by the National Institute for Health and Research through its Research for Patient Benefit programme, was strengthened by involvement from a patient and public involvement panel at the Centre for Dementia at Leeds Beckett. Its publication comes at a moment of intense public interest in dementia therapeutics, as new disease-modifying therapies enter clinical discussions worldwide and the pressure on memory clinics to communicate complex evidence grows. What this study demonstrates is that the infrastructure for those conversations, the everyday language of benefit and risk exchanged between doctor and patient, remains uneven. Standardising it, the authors argue, through guidance and decision aids, is a practical and achievable step toward ensuring that every patient with dementia receives the same honest, balanced account of what treatment can and cannot do.

Subject of Research: How clinicians communicate the benefits and side effects of dementia medications to patients in memory assessment clinics

Article Title: How do doctors discuss dementia treatments with patients? Content analysis of the presentation of treatment information, benefits and side effects

Article References: Smith, S. J., Griffiths, A. W., Knapp, P., Dickinson, R., Dooley, J., Russell, G., & Kelley, R. (2026). How do doctors discuss dementia treatments with patients? Content analysis of the presentation of treatment information, benefits and side effects. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15657-x

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15657-x

Keywords: dementia, health communication, shared decision-making, pharmacotherapy, memory clinics, content analysis, side effects, patient outcomes, geriatric care, NHS, informed consent, clinical consultation

The research, published in European Geriatric Medicine, leveraged the A/T/N classification framework, a widely adopted scheme in which ‘A’ denotes amyloid-beta pathology, ‘T’ denotes phosphorylated tau, and ‘N’ denotes neurodegeneration, typically measured as atrophy of the medial temporal lobe on CT or MRI. In this study, cerebrospinal fluid levels of amyloid-beta 42 and phosphorylated tau defined the A and T markers, while radiologists rated medial temporal atrophy using the Scheltens visual scale, with age-adjusted cut-offs determining whether a score was abnormal. Episodic memory was assessed with the Rey Auditory Verbal Learning Test, a 15-item word-list task that measures both learning across five trials and free recall after a 30-minute delay.

The cohort was deliberately naturalistic rather than curated. Unlike highly selected research samples such as the Alzheimer’s Disease Neuroimaging Initiative, the MemClin project enrolled all patients referred for neuropsychological examination across participating clinics, capturing the messy heterogeneity of real clinical practice. The final sample comprised 141 patients with Alzheimer’s disease dementia, 403 with mild cognitive impairment, and 132 with subjective cognitive impairment, with ages ranging from roughly 36 to 94 years. Diagnoses were made through multidisciplinary consensus meetings in which clinical presentation remained primary and biomarkers played a supportive role, mirroring the way most memory clinics actually operate.

Because many patients scored zero on delayed recall—a floor effect expected in a memory-clinic population—the team employed weighted least-squares regression rather than ordinary linear models, assigning observation-specific weights to stabilize variance. Six regression models tested whether age moderated the relationship between each biomarker and each memory measure, controlling for sex and education, with a Bonferroni-corrected significance threshold of p less than 0.008. The results were unambiguous for two of the three biomarkers. Abnormal amyloid-beta 42 interacted significantly with age on delayed recall, with the detrimental effect of amyloid abnormality shrinking as age increased (β = 0.14, p < 0.001). Medial temporal atrophy showed a parallel interaction (β = 0.13, p = 0.002). Both models explained about 22 percent of the variance in delayed recall performance.

Phosphorylated tau, by contrast, did not survive the statistical correction, though its interaction pattern was borderline significant and trended in the same direction. The authors suggest this may reflect the comparatively stronger specificity of phosphorylated tau as an Alzheimer-specific marker, one whose relationship to cognition may be less entangled with age than amyloid or atrophy. Previous work has indicated that phosphorylated tau levels are less strongly related to age than amyloid-beta 42 or total tau, lending plausibility to that interpretation, although the researchers caution that a non-significant interaction should not be read as proof that tau is entirely age-independent.

To pinpoint where the biomarker-cognition link begins to fail, the team stratified the sample into two-year age bands and re-ran the association between abnormal amyloid status and memory performance repeatedly across those strata. The attenuation accelerated sharply at the upper end of the age distribution: for participants aged 80 to 82 and older, abnormal amyloid-beta 42 no longer showed a statistically meaningful association with episodic memory performance, with p-values exceeding 0.36, while the association remained robust in younger bands. Medial temporal atrophy followed the same trajectory. In other words, the diagnostic sensitivity of these markers appears to erode earlier than the traditional ‘oldest old’ threshold of 85 years, a finding the authors describe as unexpected from a clinical standpoint.

The biological explanation likely lies in the sheer prevalence of Alzheimer pathology in advanced age. Autopsy and imaging studies have shown that abnormal amyloid can be detected in up to 40 percent of cognitively healthy elderly individuals, and that by the time symptoms emerge, amyloid burden has largely saturated. Neuropathological research has also demonstrated that the correlation between Alzheimer-type pathology and dementia weakens with advancing age, as vascular disease, hippocampal sclerosis, TDP-43 proteinopathy, inflammatory processes, and individual differences in cognitive reserve increasingly shape clinical outcomes. The landmark 90+ Study illustrated this vividly: roughly half of its participants without dementia nonetheless met criteria for Alzheimer pathology at autopsy. In the oldest old, medial temporal atrophy may similarly reflect a mixture of age-related processes rather than Alzheimer-specific neurodegeneration, diluting its predictive value.

The clinical implications are provocative. The authors raise the question of whether lumbar puncture and cerebrospinal fluid assessment are justified in patients older than 80, given the weak association between the biomarkers and core clinical measures such as learning and free recall. They are careful, however, to draw boundaries around that claim. The finding should not be interpreted as questioning the broader utility of CSF biomarkers, which may remain important for diagnostic evaluation, prognosis, and determining eligibility for emerging disease-modifying therapies, including anti-amyloid immunotherapies. Nor should the exploratory age-stratified analyses be treated as confirmatory; small subgroup sizes, the cross-sectional design, and the risk of type 1 error all temper the conclusions, and the authors frame these results as hypothesis-generating pending large-scale longitudinal validation.

The study also carries methodological caveats that the researchers confront directly. Participants excluded for missing data differed in age from those included—excluded dementia patients were older, while excluded MCI and SCI patients were younger—raising the possibility of selection effects, although the pattern of CSF testing being more common in younger, diagnostically challenging patients arguably makes the sample representative of real practice. Visual atrophy ratings were based on CT in 60 percent of cases and MRI in 40 percent, a combination supported by evidence of comparable inter-rater reliability. Biomarkers were evaluated individually rather than in combination, and only verbal learning and free recall were examined, leaving recognition memory, cued recall, and executive functions for future study.

What emerges is a nuanced portrait of biomarker diagnostics at the frontier of human longevity. In a naturalistic cohort spanning the full cognitive-impairment continuum, the two biomarkers most proximal to memory circuitry—amyloid and medial temporal atrophy—lost traction against advancing age, while phosphorylated tau held its pattern more steadily. If replicated longitudinally, these findings could reshape diagnostic algorithms for the fastest-growing segment of the dementia population, prompting clinicians to weigh clinical presentation more heavily and biomarkers more cautiously once patients cross their ninth decade. For now, the message is one of calibrated skepticism: the molecular signature of Alzheimer’s disease does not translate into memory impairment with equal fidelity at every age, and medicine’s most trusted biomarkers may need an age-adjusted interpretation of their own.

Subject of Research: Age-related weakening of the association between Alzheimer's disease ATN biomarkers and episodic memory in memory clinic patients

Article Title: The associations between ATN biomarkers and episodic memory diminish as age increases

Article References: Ekman, U., Gyllenhammar, M., Almkvist, O., Ocklind, A., Hallerstam, L., Ferreira, D., Eriksdotter, M., Wahlund, L.-O., Rennie, A., & Westman, E. (2026). The associations between ATN biomarkers and episodic memory diminish as age increases. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01606-8

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01606-8

Keywords: Alzheimer's disease, ATN biomarkers, amyloid-beta 42, phosphorylated tau, medial temporal atrophy, episodic memory, cerebrospinal fluid, cognitive aging, memory clinics, RAVLT, mild cognitive impairment, diagnostic biomarkers